Accurate and precise biomarker measurement is critical to identifying diagnostic markers and druggable targets. Learn how quantitative mass spectrometry ensures proper biomarker measurement and characterization.
Browsing: Mass Spectrometry
Find out more about the technologies involved in drug metabolism and what the future may hold for drug metabolism studies in drug discovery research in this ‘In the Zone’ feature.
As part of our ‘In the Zone’ feature on drug metabolism, we present the top 6 tips for LC–MS for drug metabolism studies. Find out more about best practice tip and tricks for LC–MS in this helpful infographic from MilliporeSigma (MO, USA).
Definitive profiling of plasma bile acids as potential biomarkers for human liver diseases using UPLC–HRMS
Find out more about this investigation into a thorough and rapid profiling of bile acids in human plasma in this article from Bioanalysis.
Challenged to remove matrix interferences while dealing with the evolving complexity of biotherapeutics? This presentation illustrates how SelexION+ DMS can be efficiently utilized to overcome background interference challenges, which might otherwise limit assay capabilities.
This week’s round-up includes the discovery of a novel method for mass spectometry and thermal desorption, as well as an update from Waters Corp (MA, USA) on their aquisition of DESI technology exclusive rights.
Find out more about ensuring the validity of biomarker measurements in this Editorial from Liam Heaney (University of Loughborough, UK).
In this interview, Allena Ji (Sanofi Genzyme; MA, USA) discusses the advantages and challenges of using triple quadrupole mass spectrometry, the challenges associated with increasing biomarker assay sensitivity and how the field may be regulated and standardized.
In this interview with Ragu Ramanathan (Pfizer; NY, USA), Ragu describes his current research focuses in measuring and quantitating drugs and metabolites in animal and human samples. Ragu discusses the key challenges associated with studying drug/drug interactions (DDI), the benefits of current technologies available for studying DDI and what to expect from the upcoming Special Focus Issue from Bioanalysis on ‘Novel LC–MS assays impacting CYP and transporter DDI evaluation’.
Opportunities and challenges for hybrid immunoaffinity LC–MS approach for quantitative analysis of protein biomarkers
Learn more about opportunities and challenges for hybrid immunoaffinity LC–MS approach for quantitative analysis of protein biomarkers in this article from Future Science OA.